There were fears that the Factor 9 concentrate in particular - but also Factor 8 - might give rise to a greater risk of thrombosis from the heat-treated product, although research facilities were limited, scientific staff were few, and BPL suffered from a lack of viral containment equipment. Read more about There were fears that the Factor 9 concentrate in particular - but also Factor 8 - might give rise to a greater risk of thrombosis from the heat-treated product, although research facilities were limited, scientific staff were few, and BPL suffered from a lack of viral containment equipment.
Dr Lane's view was that "the risks of transmission of HIV were such that heat treatment should be employed even if it turned out to be a temporary expedient." Read more about Dr Lane's view was that "the risks of transmission of HIV were such that heat treatment should be employed even if it turned out to be a temporary expedient."
The "Proposal to Develop a 'Hepatitis-Safe' Factor VIII Concentrate" noted that "NANBH causes increasing concern, less on account of its acute effects (although deaths have been reported) than because of its association with chronic active hepatitis in later life", and that AIDS was "not yet proven to be of viral origin, but this is strongly presumed." Read more about The "Proposal to Develop a 'Hepatitis-Safe' Factor VIII Concentrate" noted that "NANBH causes increasing concern, less on account of its acute effects (although deaths have been reported) than because of its association with chronic active hepatitis in later life", and that AIDS was "not yet proven to be of viral origin, but this is strongly presumed."
There were discussions at BPL about the degree of success commercial firms had in reducing hepatitis transmission, and answers being sought to questions about the safety and efficacy of those heat-treated concentrates which were being developed elsewhere. Read more about There were discussions at BPL about the degree of success commercial firms had in reducing hepatitis transmission, and answers being sought to questions about the safety and efficacy of those heat-treated concentrates which were being developed elsewhere.
Dr Lane in his draft proof of evidence for the HIV Haemophilia Litigation, wrote "The documentation I have discussed above indicates our intention to define a heat treatment process capable of full virus inactivation, probably requiring more severe heating than was currently recognised." Read more about Dr Lane in his draft proof of evidence for the HIV Haemophilia Litigation, wrote "The documentation I have discussed above indicates our intention to define a heat treatment process capable of full virus inactivation, probably requiring more severe heating than was currently recognised."
Dr Lane reported that "a research project into the development of coagulation factor concentrates with reduced risk of hepatitis transmission, was an appropriate case for central funding." Read more about Dr Lane reported that "a research project into the development of coagulation factor concentrates with reduced risk of hepatitis transmission, was an appropriate case for central funding."
Dr Robert Gerety and Dr David Aronson in an invited review said studies had been completed and others were underway to evaluate methods of stabilising clotting factors as heat was capable of inactivating both Hepatitis B and non-A non-B Hepatitis infectivity. Read more about Dr Robert Gerety and Dr David Aronson in an invited review said studies had been completed and others were underway to evaluate methods of stabilising clotting factors as heat was capable of inactivating both Hepatitis B and non-A non-B Hepatitis infectivity.
Parliamentary questions discussed the issue of unscreened BPL plasma and said issuable blood products which might be contaminated with AIDS had been destroyed. Read more about Parliamentary questions discussed the issue of unscreened BPL plasma and said issuable blood products which might be contaminated with AIDS had been destroyed.
An internal memo described the outcome of a meeting where Dr Savidge presented results of his profilate HT trials and that the results provided evidence to support Alpha's claim that Profilate HT was free from non-A non-B Hepatitis. Read more about An internal memo described the outcome of a meeting where Dr Savidge presented results of his profilate HT trials and that the results provided evidence to support Alpha's claim that Profilate HT was free from non-A non-B Hepatitis.
In a memo on figures of Cutte's products it showed that a small short-dated batch mentioned last month had now been sold and several other contacts had shown an interest in other batches and the material had been offered for sale. Read more about In a memo on figures of Cutte's products it showed that a small short-dated batch mentioned last month had now been sold and several other contacts had shown an interest in other batches and the material had been offered for sale.